RAPS and National University of Singapore Launch Regulatory Affairs Graduate Certificate Program
The Regulatory Affairs Professionals Society and the National University of Singapore have announced the official launch of their joint Graduate Certificate in Medical Devices Regulatory Affairs program.
The Regulatory Affairs Professionals Society (RAPS) and the National University of Singapore (NUS) have announced the official launch of their joint Graduate Certificate in Medical Devices Regulatory Affairs (MDRA) program. The program is intended for Singapore-based regulatory professionals, and was developed in partnership with the government of Singapore to cultivate an industry-ready regulatory workforce.
The MDRA program builds the foundational knowledge, critical thinking and application skills required of regulatory professionals. The curriculum will be delivered through a combination of online training, interactive seminars, peer interaction and case-based learning, and will cover regulations of ASEAN nations, China, the Asia-Pacific region, the US and Europe.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
